Indianapolis, Indiana 46254


ICAN is the first treatment to target hostile attributions after TBI, making it a novel anger/ aggression management approach in this population. This is a randomized waitlist control trial. The length of time in the trial is 15 weeks and the intervention is 6 weeks long.

Study summary:

ICAN is the first treatment to target hostile attributions after TBI, making it a novel anger/ aggression management approach in this population. Since the investigator's prior research shows that stronger hostile attributions are associated with poorer perspective taking,39 ICAN employs a unique perspective-positioning technique to train perspective taking and reduce hostile attributions. After recalling a personal situation in which others' ambiguous actions led to an unpleasant outcome, participants will explore different perspectives: sitting or standing in one position, s/he will explore his or her own thoughts and feelings (self-perspective), then move to a different position to experience the other person's perspective, eliciting their thoughts and feelings. In 40 participants with TBI, we will conduct a Phase I, randomized waitlist controlled trial with 4 data collection points: Baseline; Posttest I (post-treatment for ICAN; post-wait period for WLC); Posttest II (WLC post-treatment).


Inclusion Criteria: - History of complicated mild to severe TBI (injury due to an external physical force), with injury severity being defined either by Glasgow Coma Score at time of injury (≤12), or post-traumatic amnesia (≥1 day), or loss of consciousness (≥30 minutes), or positive head CT scan consistent with TBI. - At least 18 years of age or older; - ≥1 year post-injury; - Have adequate vision, hearing, and speech/ language skills to participate in assessments and group therapy (determined based on interaction with the participant at screening) - Have adequate reading comprehension (due to the primary assessment involving written scenarios) - Have abnormal scores of negative attributions or perspective taking (determined at T0 screening) - Have above average aggression (prescreened on telephone, and confirmed T0 screening). - No anticipated medication changes for emotions/ behavior during length of study participation; medica-tions for emotions/ behavior must be stable within last 30 days prior to consent at T0 (Screening) - Have reliable mode of transportation Exclusion criteria: - Pre-morbid neurological disorders that could affect mood and cognition (e.g. stroke) - Progressive central nervous system disorders (e.g. dementia, Parkinson's) - Developmental disability (e.g., autism, developmental delay); - Major psychiatric disorders (e.g. schizophrenia, Borderline Personality Disorder); - Severe Depression and/or perceived risk to self or others (mental health resources will be provided and if suicide risk, approved suicide protocol will be utilized); - Currently receiving active behavioral therapy for anger. - On drug research study for irritability, anger, aggression



Primary Contact:

Principal Investigator
Dawn Neumann, Phd
Indiana University School of Medicine

Ryan Mayfield
Phone: 3173292380

Backup Contact:


Location Contact:

Indianapolis, Indiana 46254
United States

Ryan Mayfield
Phone: 317-329-2380

Site Status: Recruiting

Data Source:

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.